AMAngelika Mühlebner

Angelika Mühlebner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angelika Mühlebner has a total of 247 co-authors. Here are the top co-authors by number of shared publications:

  • Eleonora Aronica

    Department of (Neuro)pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

    11 shared publications
  • Ingmar Blümcke

    Institute of Neuropathology University Hospitals Erlangen Erlangen Germany

    7 shared publications
  • Martha Feucht

    Department of Pediatrics, Medical University of Vienna, Member of the European Reference Network for Rare and Complex Epilepsies, Vienna, Austria

    7 shared publications
  • Jasper J. Anink

    Department of (Neuro)Pathology Amsterdam University Medical Center University of Amsterdam Amsterdam the Netherlands

    6 shared publications
  • Eleonora Aronica

    Amsterdam UMC, University of Amsterdam, (Neuro)Pathology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, 2103 SW Heemstede, Amsterdam, The Netherlands

    5 shared publications
  • Erwin Alexander van Vliet

    Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands

    5 shared publications

Latest Publications

  • Open Access

    Repetitive clustered low‐voltage fast activity on intracranial electroencephalogram in mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy: A candidate electroencephalographic biomarker study

    by Vadym Gnatkovsky, Ekaterina Poguzhelskaya, Valeri Borger, Tobias Baumgartner, Rainer Surges, Kerstin Alexandra Klotz, Valentina Zschernack, Till Hartlieb, Manfred Kudernatsch, Ahmed Gaballa, et al.

    Objective: Mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE) is a recently recognized cause of drug‐resistant focal epilepsy. It is often magnetic resonance imaging‐negative or radiologically resembles focal cortical dysplasias, which makes recognition difficult and limits presurgical counseling. We aimed to identify an intracranial electroencephalographic (iEEG) biomarker that distinguishes MOGHE from other developmental brain lesions encountered in epilepsy surgery. Methods: We analyzed long‐term stereo‐EEG and subdural recordings in a retrospective multicenter test cohort (18 MOGHE, 20 non‐MOGHE) to identify an iEEG pattern distinguishing MOGHE from other developmental brain lesions. We then evaluated its diagnostic performance by blinded visual assessment in an independent single‐center validation cohort (11 MOGHE, 11 non‐MOGHE). Firth‐penalized multivariable logistic regression tested whether MOGHE histology independently predicted the presence of this pattern after adjustment for spasms, frontal localization, age at seizure onset, and age at implantation. Finally, within MOGHE, we assessed whether resection of the territory exhibiting this pattern was associated with postsurgical seizure freedom. Results: We identified highly stereotyped clusters of very brief low‐voltage fast activity (LVFA), recurring in statuslike episodes lasting several minutes and sometimes lacking clear clinical symptoms. LVFA clusters occurred in 16 of 18 MOGHE and in no non‐MOGHE patients in the test cohort. In the validation cohort, visual identification of LVFA clusters correctly classified 10 of 11 MOGHE and 10 of 11 non‐MOGHE cases (overall agreement = 90.9%, 95% Wilson confidence interval = 72.2%–97.5%). MOGHE histology was the dominant independent predictor of LVFA clusters. Within MOGHE, resection of LVFA cluster territory was associated with postsurgical seizure freedom (Mann–Whitney U ‐test, p = .0021). Significance: Because LVFA clusters can be recognized visually on routine iEEG without specialized software, they may provide a clinically applicable candidate biomarker for presurgical identification of MOGHE and support surgical planning and outcome prediction. Prospective studies should validate their diagnostic and prognostic utility.

  • Open Access

    A novel diagnostic intracranial EEG biomarker in MOGHE

    by Vadym Gnatkovsky, Ekaterina Poguzhelskaya, Valeri Borger, Rainer Surges, Kerstin Alexandra Klotz, Valentina Zschernack, Till Hartlieb, Manfred Kudernatsch, Ahmed Gaballa, Thomas Cloppenborg, et al.

    Mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE) is a recently recognized cause of drug-resistant focal epilepsy. It is often MRI-negative or shows imaging features mimicking focal cortical dysplasias, which makes recognition difficult and limits presurgical counseling. We aimed to identify an intracranial EEG (iEEG) biomarker that distinguishes MOGHE from other developmental brain lesions encountered in epilepsy surgery. In a retrospective multicenter test cohort of 38 patients (18 MOGHE, 20 non-MOGHE), we analyzed long-term stereo-EEG and subdural recordings. Only MOGHE patients showed highly stereotyped clusters of very brief low-voltage fast activity (LVFA) events, organized into status-like 3 to 12-minute episodes that often lacked clear clinical symptoms. LVFA clusters were present in 16/18 MOGHE and 0/22 non-MOGHE patients. We then tested diagnostic performance in an independent, blinded single-center validation cohort of 22 patients (11 MOGHE, 11 non-MOGHE), in which visual identification of LVFA clusters correctly classified 10/11 MOGHE and 10/11 non-MOGHE cases (Cohen’s κ=0.82). Penalized logistic regression further confirmed MOGHE histology as the strongest predictor of LVFA clusters, independent of age and lobe localization. Because LVFA clusters can be recognized visually on routine intracranial EEG recordings without specialized software, this biomarker is readily applicable in clinical practice and may improve presurgical identification of MOGHE. Future prospective studies should determine whether its recognition influences surgical planning, improves outcome prediction, or facilitates selection of patients for mechanism-based therapies. Highlights: Clusters of brief LVFA in intracranial EEG are a lesion-specific biomarker of MOGHE compared to mMCD and FCD2 LVFA clusters reliably distinguished MOGHE from non-MOGHE lesions (mMCD and FCD2) in both a multicenter test cohort and an independent blinded validation cohort. Younger age at seizure onset is a secondary independent modifier, while frontal localization and age at intracranial recording are not. Clinicians can detect LVFA clusters on continuous intracranial EEG using routine montages and ≥60-second review windows, without any specialized software. LVFA clusters show a characteristic temporal organization and burden in MOGHE, indicating a distinct pattern of pathological network activity in this lesion type.


  • Open Access

    Associations of cognitive and behavioural impairment in ALS with brain pathology: pTDP-43 versus microglial activation

    by Hanneke M. J. Slaghekke, Rosanne Govaarts, Lucia Mesarosova, Angelika Mühlebner, Emma Beeldman, Marianne de Visser, Michael A. van Es, Leonard H. van Den Berg, Anneke J. van der Kooi, Yolande A. L. Pijnenburg, et al.

    Objective: Investigate associations between brain pathology (pTDP-43 inclusions and microglial activation) and cognitive and behavioural impairment in patients with amyotrophic lateral sclerosis (ALS). Methods: Based on comprehensive neuropsychological examination and behavioural assessment, 21 ALS patients of whom post mortem brain tissue was obtained, were classified as having 1) no cognitive and/or behavioural impairment (pure motor ALS), 2) mild cognitive and/or behavioural impairment (ALSci/bi), and 3) ALS with behavioural variant frontotemporal dementia (ALS-bvFTD). Immunohistochemical staining of pTDP-43 and HLA-DR-defined microglial activation was semi-quantitatively assessed in grey and/or white matter of the prefrontal cortex, thalamus, hippocampus, and motor cortex. Results: Fourteen patients had pure motor ALS, four patients had ALSci/bi, and three patients had ALS-bvFTD. pTDP-43 pathology in the grey matter of the prefrontal cortex and gyrus dentatus differed between groups, especially between pure motor ALS and ALS-bvFTD. For each extra-motor brain region, pTDP-43 severity was highest in patients with ALS-bvFTD and lowest in patients with pure motor ALS, with ALSci/bi in between. This pattern was not observed for microglial activation. Associations between white matter pTDP-43 severity and cognitive/behavioural impairment were less robust than those in grey matter. Conclusion: Severity of cognitive and/or behavioural impairment in ALS is related to severity of pTDP-43 pathology, in particular in the grey matter of extra-motor brain regions; we did not detect a clear association with microglial activation.

  • Current management of low‐grade, epilepsy‐associated brain tumors in Europe

    by Alexis Arzimanoglou, Sébile Tchaicha, Belén Trebino Harrington, Angelika Mühlebner, Imad Najm, Ingmar Blümcke

    Low‐grade epilepsy‐associated brain tumors (LEATs) are a frequent cause of drug‐resistant focal epilepsy in both children and adults. Epilepsy surgery is a well‐recognized treatment option, with almost 80% of patients being seizure‐free at 1 year, and 50% of children being seizure‐ and drug‐free at 5 years. Despite these outcomes, standardized management guidelines remain lacking. The present study aimed to assess current practices in Europe. A comprehensive web‐based survey was conducted by EpiCARE (European Reference Network for Rare and Complex Epilepsies). Responses were collected from 172 clinicians representing 75 institutions in 26 European region countries. The questionnaire addressed institutional protocols, individual practices, referral pathways, presurgical evaluation, histopathology, molecular diagnostics, and follow‐up. Clinicians largely agreed that epileptic seizures are a major comorbidity in LEAT patients, and most reported that seizure frequency and duration influence their treatment approach. This reflects an understanding of LEATs not only as an oncological entity, but above all as an epileptogenic lesion with a strong impact on quality of life, systematically requiring a multidisciplinary approach. Significant inconsistencies were identified, particularly regarding referral pathways, presurgical assessment (66% referred systematically to an epilepsy team), and molecular diagnostics. Only 48% of respondents reported having institutional protocols in place. Although the majority supported early referral to an epilepsy surgery team after diagnosis (even in the absence of confirmed drug resistance), 13% still required failure of at least two antiseizure medications. Long‐term postsurgical follow‐up was recommended by 89% of clinicians beyond 1 year after surgery. Almost all clinicians acknowledged that histopathology influenced clinical decision‐making for follow‐up, and 87.2% were familiar with the World Health Organization 2021 central nervous system tumor classification and molecular diagnostics. This large European study shows growing alignment with international recommendations, but significant inconsistencies remain in clinical practice, particularly regarding referral pathways, presurgical assessment, and molecular diagnostics. These findings highlight the need for consensus‐driven international guidelines for LEAT management.


  • Diagnosing primary lateral sclerosis: a clinico-pathological study

    by Eva M. J. de Boer, Bálint S. de Vries, Wim Van Hecke, Angelika Mühlebner, Koen L. Vincken, Christian P. Mol, Wouter van Rheenen, Henk-Jan Westeneng, Jan H. Veldink, Günter U. Höglinger, et al.

    Background Primary lateral sclerosis (PLS) is a rare motor neuron disease characterized by upper motor neuron degeneration, diagnosed clinically due to the absence of a (neuropathological) gold standard. Post-mortem studies, particularly TDP-43 pathology analysis, are limited. Methods This study reports on 5 cases in which the diagnostic criteria for PLS were met, but in which neuropathology findings showed (partially) conflicting results. These discrepancies prompted us to perform a clinico-pathology study focussing on diagnostic challenges and accuracy in PLS. To this end, all cases were reviewed by an international panel of 11 experts using an e-module and structured questionnaires. Results Autopsy exhibited neuropathological findings consistent with amyotrophic lateral sclerosis (ALS) in one case, while two cases exhibited similar, but more limited lower motor neuron involvement, hinting at PLS or ALS overlap. Another case displayed tau-pathology indicative of progressive supranuclear palsy. The final case displayed extensive myelin loss without a proteinopathy or a clear diagnosis. The expert panel identified 24 different ancillary investigations lacking across cases (e.g. genetic testing, DAT scans, neuropsychological evaluation), listed 28 differential diagnoses, and identified 13 different conditions as the most likely diagnosis. Autopsy results led panel members to change their final diagnosis in 42% of the cases. Conclusions This study underscores the diagnostic challenges posed by diverse underlying pathologies resulting in upper motor neuron phenotypes. Despite adhering to the same diagnostic criteria, consensus amongst experts was limited. Ensuring the diagnostic consistency is crucial for advancing understanding and treatment of PLS. Explicit guidelines for excluding potential mimics along with a neuropathological gold standard are imperative.


  • Open Access

    Single-cell profiling of cortical tubers in tuberous sclerosis complex shows molecular structure preservation and massive reorganization of metabolism

    by Frederik Nørby Friis Sørensen, Tin Luka Petanjek, Mirte Scheper, Rasmus Rydbirk, Irina Korshunova, Jasper Anink, Angelika Mühlebner, James D. Mills, Zdravko Petanjek, Eleonora Aronica, et al.

    Tuberous sclerosis complex (TSC) is a multisystemic genetic disorder associated with loss-of-function mutations in the TSC1 or TSC2 gene, which lead mTOR pathway hyperactivation and epileptogenesis. Cortical tubers are the hallmark of TSC and represent disorganized cortical structure underlying the generation of focal seizures. Here, we report single-nucleus RNA sequencing in resected cortical tubers vs matched pediatric controls. Strikingly, in spite of severe cortical disorganization, we found that cortical tubers preserve all neuronal subtypes, even the rarest ones. Moreover, we showed that principal neurons largely preserve spatial position based on transcriptional signatures. Principal neurons and layer 1-2 GABAergic neurons that modulate upper cortical circuits exhibited the largest gene expression changes. Interestingly, multiple mTOR pathway gene expression changes in TSC counteracted mTOR hyperactivation. TSC neuronal, but not glial, networks exhibited massive metabolic reorganization with a reduction in mitochondrial respiration and a concomitant switch to fatty acid metabolism. Finally, we show that neuron-specific AMPA receptor signaling might underlie epileptogenesis in TSC and could represent a potential candidate for therapeutic targeting.


  • Open Access

    Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4

    by L. P. Priesterbach-Ackley, F. Cordier, P. de Witt Hamer, T. J. Snijders, P. A. Robe, B. Küsters, W. W. J. de Leng, W. F. A. Den Dunnen, D. Brandsma, C. Jansen, et al.


  • T2-FLAIR Mismatch: An Imaging Biomarker for Children’sMYB/MYBL1–Altered Diffuse Astrocytoma or Angiocentric Glioma

    by E.A. van Maren, J.W. Dankbaar, P. Wesseling, S. Plasschaert, A. Muhlebner, E.W. Hoving, P.A. Robe, T.J. Snijders, R. Hoogendijk, M.E.G. Kranendonk, et al.

    BACKGROUND AND PURPOSE: T2-FLAIR mismatch is a highly specific imaging biomarker of IDH-mutant diffuse astrocytoma in adults. It has however also been described in MYB/MYBL1–altered low grade tumors. Our aim was to assess the diagnostic power of the T2-FLAIR mismatch in IDH-mutant astrocytoma and MYB/MYBL1–altered low-grade tumors in children and correlate this mismatch with histology. MATERIALS AND METHODS: We evaluated MR imaging examinations of all pediatric patients, performed at the Princess Máxima Center for Pediatric Oncology and the University Medical Center Utrecht between January 2012 and January 2023, with the histomolecular diagnosis of IDH-mutant astrocytoma, diffuse astrocytoma MYB/MYBL1–altered, or angiocentric glioma, and the presence of T2-FLAIR mismatch was assessed. Histologically, the presence of microcysts in the tumor (a phenomenon suggested to be correlated with T2-FLAIR mismatch in IDH-mutant astrocytomas in adults) was evaluated. RESULTS: Nineteen pediatric patients were diagnosed with either IDH-mutant astrocytoma (n = 8) or MYB/MYBL1–altered tumor (n = 11: diffuse astrocytoma, MYB- or MYBL1-altered n = 8; or angiocentric glioma n = 3). T2-FLAIR mismatch was present in 11 patients, 3 (38%) in the IDH-mutant group and 8 (73%) in the MYB/MYBL1 group. No correlation was found between T2-FLAIR mismatch and the presence of microcysts or an enlarged intercellular space in either IDH-mutant astrocytoma (P = .38 and P = .56, respectively) or MYB/MYBL1–altered tumors (P = .36 and P = .90, respectively). CONCLUSIONS: In our pediatric population, T2-FLAIR mismatch was more often found in MYB/MYBL1–altered tumors than in IDH-mutant astrocytomas. In contrast to what has been reported for IDH-mutant astrocytomas in adults, no correlation was found with microcystic changes in the tumor tissue. This finding challenges the hypothesis that such microcystic changes and/or enlarged intercellular spaces in the tissue of these tumors are an important part of explaining the occurrence of the T2-FLAIR mismatch.


  • Open Access

    Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors

    by Jody M. de Jong, Diede W. M. Broekaart, Anika Bongaarts, Angelika Mühlebner, James D. Mills, Erwin A. van Vliet, Eleonora Aronica

    Seizures are one of the most common symptoms of brain tumors. The incidence of seizures differs among brain tumor type, grade, location and size, but paediatric-type diffuse low-grade gliomas/glioneuronal tumors are often highly epileptogenic. The extracellular matrix (ECM) is known to play a role in epileptogenesis and tumorigenesis because it is involved in the (re)modelling of neuronal connections and cell-cell signaling. In this review, we discuss the epileptogenicity of brain tumors with a focus on tumor type, location, genetics and the role of the extracellular matrix. In addition to functional problems, epileptogenic tumors can lead to increased morbidity and mortality, stigmatization and life-long care. The health advantages can be major if the epileptogenic properties of brain tumors are better understood. Surgical resection is the most common treatment of epilepsy-associated tumors, but post-surgery seizure-freedom is not always achieved. Therefore, we also discuss potential novel therapies aiming to restore ECM function.


  • Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway

    by Romina Moavero, Angelika Mühlebner, Mark Jasper Luinenburg, Dana Craiu, Eleonora Aronica, Paolo Curatolo